Reuters logo
BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma
September 18, 2017 / 10:22 AM / 3 months ago

BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma

Sept 18 (Reuters) - Soligenix Inc

* Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below